Cargando…
Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine
Seasonal influenza vaccine formulations must be updated annually to correspond to the influenza viruses in circulation. This was an uncontrolled, open-label, multi-center phase IV study conducted in Belgium to comply with interim European Medicines Agency (EMA) guidelines for rapidly evaluating the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404648/ https://www.ncbi.nlm.nih.gov/pubmed/27960593 http://dx.doi.org/10.1080/21645515.2016.1253644 |
_version_ | 1783231626657923072 |
---|---|
author | Demeulemeester, Marc Lavis, Nathalie Balthazar, Yohan Lechien, Patrice Heijmans, Stéphane |
author_facet | Demeulemeester, Marc Lavis, Nathalie Balthazar, Yohan Lechien, Patrice Heijmans, Stéphane |
author_sort | Demeulemeester, Marc |
collection | PubMed |
description | Seasonal influenza vaccine formulations must be updated annually to correspond to the influenza viruses in circulation. This was an uncontrolled, open-label, multi-center phase IV study conducted in Belgium to comply with interim European Medicines Agency (EMA) guidelines for rapidly evaluating the safety of newly formulated seasonal influenza vaccines. Adult volunteers received one dose of the 2014-2015 Northern Hemisphere formulation of licensed intradermal trivalent influenza vaccine at either the standard dose (9µg hemagglutinin/strain for 18−59 year-olds) or the high dose (15µg hemagglutinin/strain for ≥ 60 year-olds). Vaccinees recorded their solicited reactions and unsolicited adverse events for 7 d after vaccination. Solicited reaction frequencies were compared to historical reference values obtained from previous clinical trials to determine if the new formulations were excessively reactogenic or allergenic. A total of 210 participants (105 per age group) were included and vaccinated in October 2014. In both groups, pain, erythema, and pruritus were the most common solicited injection site reactions, and headache and myalgia were the most common solicited systemic reactions. Although the frequencies of shivering in 18−59 year-olds and malaise in ≥ 60 year-olds were higher than historical reference values, they were not considered indicative of excessive reactogenicity because almost all of these reactions were mild. The study design was endorsed by the EMA and permitted the reactogenicity of both vaccine formulations to be assessed within one month by collecting adverse events for 7 d. Both formulations exhibited acceptable safety profiles although this should be confirmed through forthcoming enhanced post-marketing safety surveillance systems. |
format | Online Article Text |
id | pubmed-5404648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-54046482017-05-03 Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine Demeulemeester, Marc Lavis, Nathalie Balthazar, Yohan Lechien, Patrice Heijmans, Stéphane Hum Vaccin Immunother Research Papers Seasonal influenza vaccine formulations must be updated annually to correspond to the influenza viruses in circulation. This was an uncontrolled, open-label, multi-center phase IV study conducted in Belgium to comply with interim European Medicines Agency (EMA) guidelines for rapidly evaluating the safety of newly formulated seasonal influenza vaccines. Adult volunteers received one dose of the 2014-2015 Northern Hemisphere formulation of licensed intradermal trivalent influenza vaccine at either the standard dose (9µg hemagglutinin/strain for 18−59 year-olds) or the high dose (15µg hemagglutinin/strain for ≥ 60 year-olds). Vaccinees recorded their solicited reactions and unsolicited adverse events for 7 d after vaccination. Solicited reaction frequencies were compared to historical reference values obtained from previous clinical trials to determine if the new formulations were excessively reactogenic or allergenic. A total of 210 participants (105 per age group) were included and vaccinated in October 2014. In both groups, pain, erythema, and pruritus were the most common solicited injection site reactions, and headache and myalgia were the most common solicited systemic reactions. Although the frequencies of shivering in 18−59 year-olds and malaise in ≥ 60 year-olds were higher than historical reference values, they were not considered indicative of excessive reactogenicity because almost all of these reactions were mild. The study design was endorsed by the EMA and permitted the reactogenicity of both vaccine formulations to be assessed within one month by collecting adverse events for 7 d. Both formulations exhibited acceptable safety profiles although this should be confirmed through forthcoming enhanced post-marketing safety surveillance systems. Taylor & Francis 2016-12-14 /pmc/articles/PMC5404648/ /pubmed/27960593 http://dx.doi.org/10.1080/21645515.2016.1253644 Text en © 2017 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Research Papers Demeulemeester, Marc Lavis, Nathalie Balthazar, Yohan Lechien, Patrice Heijmans, Stéphane Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
title | Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
title_full | Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
title_fullStr | Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
title_full_unstemmed | Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
title_short | Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
title_sort | rapid safety assessment of a seasonal intradermal trivalent influenza vaccine |
topic | Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404648/ https://www.ncbi.nlm.nih.gov/pubmed/27960593 http://dx.doi.org/10.1080/21645515.2016.1253644 |
work_keys_str_mv | AT demeulemeestermarc rapidsafetyassessmentofaseasonalintradermaltrivalentinfluenzavaccine AT lavisnathalie rapidsafetyassessmentofaseasonalintradermaltrivalentinfluenzavaccine AT balthazaryohan rapidsafetyassessmentofaseasonalintradermaltrivalentinfluenzavaccine AT lechienpatrice rapidsafetyassessmentofaseasonalintradermaltrivalentinfluenzavaccine AT heijmansstephane rapidsafetyassessmentofaseasonalintradermaltrivalentinfluenzavaccine |